Back to Research

Organization profile

Hylomorph

Hylomorph is a medtech company that develops bio-engineered, anti-fibrotic solutions to prevent postoperative complications in implantable medical devices. Its core technology, a bioresorbable surgical membrane, optimizes the interface between biological tissue and implants to reduce infection, fibrosis, and the need for revision surgeries.

Zurich, SwitzerlandFounded 2014

Overview

1. Executive Summary (Confidence: High)

Hylomorph AG, a 2014 ETH Zurich spin-off, has emerged as a disruptive leader in preventive surgical solutions for the implantable device market.[18] The company’s flagship platform, Vesta, addresses the two most critical complications in cardiac implants: fibrotic encapsulation and systemic infection.[20] After graduating from the Wyss Zurich accelerator in 2022, Hylomorph has successfully raised over $18 million in total funding, including an oversubscribed Series B2 round in 2023.[22] With a recent CHF 2.[4] million Innosuisse Swiss Accelerator grant, Hylomorph is currently transitioning to market launch in the US and EU, positioning its bioresorbable drug-eluting envelopes as the future gold standard for cardiac rhythm management (CRM) and neuromodulation.[19]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.